Kymera Therapeutics Stock (NASDAQ:KYMR)
Previous Close
$42.30
52W Range
$22.35 - $53.27
50D Avg
$46.16
200D Avg
$41.36
Market Cap
$2.53B
Avg Vol (3M)
$446.06K
Beta
2.22
Div Yield
-
KYMR Company Profile
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
KYMR Performance
Peer Comparison
| Ticker | Company |
|---|---|
| CGEM | Cullinan Oncology, Inc. |
| RVMD | Revolution Medicines, Inc. |
| IPSC | Century Therapeutics, Inc. |
| NRIX | Nurix Therapeutics, Inc. |
| PRLD | Prelude Therapeutics Incorporated |
| FHTX | Foghorn Therapeutics Inc. |
| MLYS | Mineralys Therapeutics, Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| CCCC | C4 Therapeutics, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| STTK | Shattuck Labs, Inc. |
| AGIO | Agios Pharmaceuticals, Inc. |